How FDA lab test rules are reshaping diagnostics
How the FDA’s new rules on lab tests are changing diagnostics has become a story of regulation, litigation and market power. In May 2024, the US Food and Drug Administration finalised a policy for laboratory-developed tests, or LDTs. In March 2025, a federal court in Texas vacated it, and FDA did not appeal. The episode still matters because laboratories, investors and clinicians have already reshaped plans around the expectations it created.
An LDT is designed, manufactured and used inside a clinical laboratory rather than sold as a conventional test kit. Examples include specialised panels for inherited cancer risk, rare immune disorders, fertility and pharmacogenomics. These tests can reach patients quickly because a hospital laboratory does not need a device submission for every assay, although gaps in oversight can also make their evidence harder to compare.
Australia encounters these shifts through research partnerships, US market expansion and debate about control of diagnostic data. The local system differs: the Therapeutic Goods Administration regulates commercial in-vitro diagnostic devices, while accredited pathology laboratories operate under quality, accreditation and state or territory requirements. The comparison below sets the two regulatory models side by side before examining what Australian providers and patients may inherit from the US debate.
| Issue | United States | Australia |
|---|---|---|
| Main regulator | FDA under federal law, with states overseeing some laboratory practices | TGA for diagnostic devices, plus state and territory and Medicare requirements for pathology |
| Commercial devices | Clearance or approval through pathways such as 510(k), De Novo or PMA | Commercial IVDs generally require inclusion in the Australian Register of Therapeutic Goods |
| Laboratory-developed tests | The 2024 LDT rule was vacated in 2025; other federal and state oversight remains | LDTs generally rely on laboratory accreditation, quality controls and applicable practice laws |
| Quality framework | FDA quality-system, reporting and investigational-device requirements for regulated manufacturers | TGA conformity assessment for listed devices, alongside NATA or RCPA accreditation for pathology laboratories |
What the FDA attempted to change
The 2024 policy would have phased LDT manufacturers into the medical-device framework over five years. It introduced registration and listing duties, quality-system requirements, device reporting, corrections and removals, and investigational-device controls for certain research involving LDTs. The central concern was that some tests reached patients without the same premarket scrutiny applied to commercial devices.
Its reversal did not erase those concerns. FDA still regulates commercial devices, certified laboratories remain subject to federal laboratory requirements, and states retain their own oversight powers. Possible congressional action or replacement guidance means the policy debate has shifted from a formal rule towards a choice between a new federal framework or continued reliance on laboratory accreditation and state regulation.
Why laboratories faced disruption
Compliance with the FDA policy required investment before a test had a large revenue base. A laboratory might need to establish manufacturing controls, document analytical and clinical validation, create complaint and reporting systems, and monitor performance after release. For a hospital unit testing a handful of samples for one rare condition, those fixed costs can outweigh the income generated by the test.
Managers at large diagnostic companies and smaller laboratories consequently considered converting specialised LDTs into packaged IVDs, withdrawing marginal assays or joining commercial networks. That response can improve consistency and documentation, but it may also reduce local choice and place common conditions behind larger corporate systems. The uncertainty surrounding the court decision made hiring, pricing and product development unusually difficult.
How Australia regulates laboratory testing
The Therapeutic Goods Act 1985 is the main federal law covering IVDs. Commercial products, including many self-tests, generally need assessment and inclusion in the Australian Register of Therapeutic Goods before supply. A laboratory-developed test made and performed within an accredited pathology laboratory does not follow exactly the same premarket route, creating a distinction that Australian regulators have continued to examine.
Pathology quality also rests on accreditation under Medicare requirements, with NATA and the Royal College of Pathologists of Australasia assessing laboratories against standards including ISO 15189. State and territory laws add requirements for pathology practices and clinical conduct. This layered system gives ordinary pathology services substantial oversight even where an individual assay has not been separately listed by TGA.
Australian habits differ from the market US laboratories were trying to enter. Most routine blood tests remain doctor-ordered and are processed in accredited facilities, rather than being purchased as home kits. Sydney, Melbourne and Brisbane have dense networks of collection centres and major providers such as Sonic Healthcare and Australian Clinical Labs. Regional NSW, Queensland and Western Australia depend more heavily on courier logistics, visiting collection services and links to metropolitan laboratories, making laboratory access a practical issue of distance as well as regulation.
Effects on patients and the local market
Tighter oversight can increase confidence by requiring clearer evidence, traceability and post-market monitoring. Yet additional validation and regulatory work can raise prices, particularly for niche tests used by small numbers of patients. The central policy trade-off is therefore not simply safety versus innovation, but whether consumers gain trustworthy options without losing access to tests that serve specialised clinical needs.
The pandemic demonstrated both sides of that balance. Australia relied on rapid validation and national coordination during COVID-19, while regulatory preparation for emergency use showed how quickly laboratories could document performance. The same experience highlighted the value of maintaining testing capacity between crises. For Australian consumers, stable access to common diagnostics and rapid access to novel assays remain more important than the label used to describe who developed them.
Research, genomics and cross-border trade
American universities and hospitals frequently study genomic findings by analysing samples and returning results to participants. Under the vacated FDA framework, some studies faced questions about investigational-device oversight, informed consent and independent review. Australian institutions generally work through National Health and Medical Research Council ethics processes, privacy requirements and relevant state rules, producing a different regulatory model for the same scientific activity.
Cross-border services require greater care. An Australian company selling a packaged diagnostic kit into the United States would normally need to satisfy FDA requirements for an ordinary IVD, regardless of the test’s origins. A service that only analyses specimens in Australia may occupy a different legal position. Companies must therefore separate laboratory services, research programmes and products placed commercially into the US market rather than assuming one approval covers every activity.
Costs, competition and corporate priorities
Concentration in diagnostics has increased attention to margins and ownership. Those tensions sit within a wider business environment in which corporate profits staying high attract political scrutiny. Pathology economics are also shaped by skilled-labour costs, collection networks, equipment utilisation and Medicare reimbursement, so revenue figures alone do not reveal whether competition is benefiting patients.
For regional and remote communities, cost can determine whether a specialised test is offered locally or requires an interstate referral and courier journey. Equity therefore extends beyond the price printed on a test request. It includes whether Aboriginal and Torres Strait Islander patients, people in remote areas and those without easy transport can obtain the same diagnostic pathways as patients in metropolitan centres.
What to watch and why it matters
Several developments will shape the next stage: possible US legislation on LDT oversight, revised FDA guidance, action by Australian states, any TGA assessment of laboratory-developed tests, and changes to Medicare pathology funding. Reports of poor performance, biased interpretations or withdrawn assays will also influence policy more effectively than abstract arguments about innovation.
Follow WorldIndependant for verified reporting on diagnostics, regulation and public health, sign in for updates, and use its writing submissions channel to contribute specialist analysis on how laboratory testing affects patients and health systems.